Novo Nordisk will launch a new insulin pen, designed to meet the needs of children with diabetes, in several countries next year.
The NovoPen Echo will be the first insulin pen to combine a memory function, which displays when and how much insulin has been delivered, with a half-unit dosing option, which enables more accurate dosing.
“A memory on the pen allows parents and children to check and prevent omission or double injections,” said Doctor MD Carine de Beaufort, Clinique Pediatrique de Luxembourg. “Understanding unexpected blood glucose values is easier if one knows at least what has happened to one of the variants, insulin.”
Additional child-friendly features of the NovoPen Echo are its ease of use and the option of customising the pen with a range of colourful skins.
A recent study found that, on average, 8 out of 10 children, parents and healthcare professionals rated NovoPen Echo as their favourite pen in terms of memory function, design and ease of use. In addition, 87% of the participants said they would be very likely to switch to NovoPen Echo from their current pens.
Based in Denmark, Novo Nordisk is a world leader in diabetes care. It launched the first modern insulin pen, NovoPen, in 1985.
NovoPen Echo with colour skins